**Question:** Pitolisant is approved for treatment of

A. Narcolepsy
B. Schizophrenia
C. Parkinson's disease
D. Alzheimer's disease

**Correct Answer:** A. Narcolepsy

**Core Concept:**
Pitolisant is a medication that belongs to a class of drugs known as wakefulness-promoting agents. These agents are used to treat conditions characterized by excessive daytime sleepiness and/or disrupted nocturnal sleep, such as narcolepsy. Narcolepsy is a chronic neurological disorder in which an individual experiences excessive daytime sleepiness, sleep paralysis, hypnagogic hallucinations, and cataplexy (sudden loss of muscle tone triggered by strong emotions).

**Why the Correct Answer is Right:**
Pitolisant is a selective histamine H3 receptor antagonist and partial agonist. Histamine plays a crucial role in regulating sleep-wake cycle, with histamine neurons in the tuberomamillary nucleus of the hypothalamus being the primary source of histamine in the central nervous system. By blocking H3 receptors, pitolisant increases histamine levels, which enhances alertness and reduces sleepiness.

**Why Each Wrong Option is Incorrect:**

A. Schizophrenia is a primary psychiatric disorder characterized by disorganized thinking, delusions, hallucinations, and negative symptoms. It is primarily treated with antipsychotic medications, not wakefulness-promoting agents like pitolisant.

B. Schizophrenia is a primary psychiatric disorder characterized by disorganized thinking, delusions, hallucinations, and negative symptoms. It is primarily treated with antipsychotic medications, not wakefulness-promoting agents like pitolisant.

C. Parkinson's disease is a progressive neurodegenerative disorder affecting movement, resulting from the loss of dopaminergic neurons in the substantia nigra. Treatment options for Parkinson's disease involve dopaminergic agents like levodopa and dopamine agonists, not wakefulness-promoting agents like pitolisant.

D. Alzheimer's disease is a progressive neurodegenerative disorder affecting memory, thinking, and behavior. Treatment options for Alzheimer's disease involve cholinesterase inhibitors and NMDA receptor antagonists, not wakefulness-promoting agents like pitolisant.

**Clinical Pearl:**
In summary, pitolisant is a specific medication indicated for the treatment of narcolepsy, which is a sleep disorder characterized by excessive daytime sleepiness. Narcolepsy affects an individual's daily functioning as they experience sudden urges to sleep, cataplexy attacks, and abnormal sleep propensity. Narcolepsy is managed with medications that target the sleep-wake cycle, such as wakefulness-promoting agents like pitolisant, as it helps in modulating histamine neurotransmission and thereby improving wakefulness.